Role of Combination Therapy in Women With Refractory Overactive Bladder

NANot yet recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2026

Conditions
Overactive Bladder Syndrome
Interventions
DRUG

Vibegron 75mg

Each patient will undergo intradetrusor onabotulinumtoxinA injections of 100U either in the office or in the operating room depending on patient and provider preference. Patients will begin taking vibegron 75mg daily or a placebo pill daily starting the day of their procedure and continue for 3 months.

DRUG

Placebo

Each patient will undergo intradetrusor onabotulinumtoxinA injections of 100U either in the office or in the operating room depending on patient and provider preference. Patients will begin taking vibegron 75mg daily or a placebo pill daily starting the day of their procedure and continue for 3 months.

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT06438861 - Role of Combination Therapy in Women With Refractory Overactive Bladder | Biotech Hunter | Biotech Hunter